T: 0131-244 2528 F: 0131-244 2375 E: irene.fazakerley@scotland.gsi.gov.uk 18 November 2009



IMMEDIATE MESSAGE TO:

- 1. Directors of Pharmacy
- 2. Chief Pharmacists, NHS Boards
- 3. Hospital Pharmacy Managers
- 4. Medical Directors NHS Boards
- 5. Chief Executives NHS Boards

Dear Healthcare Professional,

DRUG ALERT NO 30 – CLASS 2

Please find attached revised drug safety information from the Medicines and Healthcare Products Regulatory Agency (MHRA) for onward transmission (see list below).

- 1. Please could Directors of Pharmacy forward this alert to:-
 - Community Pharmacists
 - Hospital pharmacists
 - Chief Pharmacists to forward on to Medicines Information Pharmacists
- 2. Please could Medical Directors forward the message on to :-
 - General Practitoners
 - Dispensing Doctors
 - Relevant Clinics
 - Chief Executives NHS Boards

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY Pharmacy Division

* NB: Drug alerts have the following classifications:

1. Action now (including out-of-hours); 2. Action within 48 hours; 3. Action within 5 days; 4 Caution in use



Safeguarding public health Defective Medicines Report Centre Market Towers 1 Nine Elms Lane London SW8 5NQ Telephone: +44 (0)20 7084 2574



DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours PHARMACY OR EQUIVALENT LEVEL RECALL

Fax: +44 (0)20 7084 2676

Date: 18 November 2009	EL (09)A/30	Our Ref: MDR 04-10/09				
Dear Healthcare Professional,						
Pinewood Laboratories Limited						
Boots Heartburn Relief Peppermint Flavour		PL 04917/0027				
Peptac Peppermint Liquid Pharmaceuticals UK)	d (Ivax	PL 04917/0027				
Peptac Liquid Aniseed FI Pharmaceuticals UK)	avour (Ivax	PL 04917/0021				

(Oral suspensions containing sodium alginate 250mg, sodium bicarbonate 133.5mg and calcium carbonate 80mg per 5ml)

Boots Heartburn Relief Peppermint Flavour

Batch Number	Expiry Date	Pack Size	First Distributed
41808	31/12/2010	500ml bottle	June 2009

Peptac Peppermint Liquid (Ivax Pharmaceuticals UK livery)

Batch Number	Expiry Date	Pack Size	First Distributed
41808	31/12/2010	500ml bottle	February 2009
41957	31/01/2011	500ml bottle	March 2009

MHRA Distribution: Regional Contacts for NHS Trusts and Provider Units Chief Pharmacists: England, Scotland, Wales, Northern Ireland Prison Health Policy Unit (DH) Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar Special Hospitals Healthcare Commission for distribution to Independent Health Care Establishments Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency Market Towers 1 Nine Elms Lane London SW8 5NQ T 020 7084 2000 F 020 7084 2353 www.mhra.gov.uk

An executive agency of the Department of Health



Date: 18 November 2009

EL (09)A/30

MDR 04-10/09

Peptac Liquid Aniseed Flavour (Ivax Pharmaceuticals UK livery)

Batch Number	Expiry Date	Pack Size	First Distributed
41757	30/11/2010	500ml bottle	March 2009

Pinewood Laboratories Limited are recalling the above lots due to a low-level microbial contamination detected in a small number of samples from these batches. The contamination causes spoilage of the product and a phenolic or antiseptic smell. The products should smell of peppermint or aniseed.

The microbial contamination is not likely to be harmful to normally healthy consumers. However, if these products are being used by patients with suppressed immune systems, such as patients on chemotherapy, the risk of infection and other adverse reactions cannot be ruled out. General Practitioners or Pharmacists receiving enquiries from such patients are requested to give professional advice and refer to the responsible treatment centre where necessary.

For Medical Information enquiries, please call Pinewood Laboratories Limited on 00353 52 6136253

For any other queries relating to the Boots product, please contact Central Customer Care on 08450 708090

For all queries relating to stock of the Ivax products please contact: Jane Booth, Customer Liaison manager, Teva UK Limited on Freephone 0800 590502

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care Trusts are asked to forward this to relevant clinics and to General practitioners and Community Pharmacists for information.

Yours faithfully

Alison Bunce Pharmaceutical Assessor, DMRC